CenterBook Partners LP cut its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 80.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 690,077 shares of the company's stock after selling 2,791,929 shares during the quarter. CenterBook Partners LP owned about 0.46% of Xeris Biopharma worth $2,339,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Xeris Biopharma by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock worth $26,778,000 after purchasing an additional 133,738 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Xeris Biopharma by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock worth $11,364,000 after acquiring an additional 17,956 shares in the last quarter. AIGH Capital Management LLC grew its stake in Xeris Biopharma by 17.8% in the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company's stock valued at $8,729,000 after acquiring an additional 389,192 shares during the period. Renaissance Technologies LLC grew its stake in Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock valued at $7,115,000 after acquiring an additional 500,120 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Xeris Biopharma by 166.2% in the fourth quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock worth $3,537,000 after acquiring an additional 651,481 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.
Xeris Biopharma Trading Up 3.4 %
Shares of XERS traded up $0.14 during midday trading on Tuesday, reaching $4.30. The stock had a trading volume of 848,514 shares, compared to its average volume of 1,853,195. The firm has a 50 day simple moving average of $4.40 and a 200-day simple moving average of $3.67. The firm has a market cap of $661.94 million, a PE ratio of -9.56 and a beta of 1.37. Xeris Biopharma Holdings, Inc. has a one year low of $1.69 and a one year high of $6.07.
Analyst Ratings Changes
Several brokerages recently issued reports on XERS. Craig Hallum boosted their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Jefferies Financial Group reissued a "buy" rating and issued a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, Leerink Partners increased their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $6.10.
Get Our Latest Research Report on XERS
Insiders Place Their Bets
In other news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. The trade was a 2.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.56% of the company's stock.
Xeris Biopharma Company Profile
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Read More
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
